Retatrutide, an investigational drug developed by Eli Lilly, is currently in late-stage clinical trials and is being hailed as a potential breakthrough in the treatment of obesity and type-2 diabetes. This once-weekly injection acts as a triple hormone receptor agonist, targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. The unique combination of these three receptors is believed to regulate appetite, energy balance, and metabolism effectively. In a recent phase-3 study, participants using retatrutide lost an average of 16.6 kg (16.8%) over 40 weeks, demonstrating significant weight-loss potential. Experts suggest that retatrutide could also offer longevity benefits, appealing to a broader patient population that may not have responded to existing weight-loss drugs like semaglutide. Eli Lilly is exploring retatrutide's efficacy in treating knee osteoarthritis and other conditions, indicating its versatility in metabolic health management.